NASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Price, News & Analysis $8.08 +0.02 (+0.25%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$7.91▼$8.3450-Day Range$5.86▼$9.9852-Week Range$3.19▼$12.09Volume63,743 shsAverage Volume338,048 shsMarket Capitalization$249.49 millionP/E RatioN/ADividend YieldN/APrice Target$23.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Acrivon Therapeutics alerts: Email Address Acrivon Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside186.4% Upside$23.14 Price TargetShort InterestBearish4.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.40) to ($2.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.28 out of 5 starsMedical Sector700th out of 910 stocksPharmaceutical Preparations Industry329th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingAcrivon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAcrivon Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Acrivon Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.68% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Acrivon Therapeutics has recently decreased by 1.94%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRV. Previous Next 1.9 News and Social Media Coverage News SentimentAcrivon Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Acrivon Therapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.50% of the stock of Acrivon Therapeutics is held by insiders.Percentage Held by Institutions71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acrivon Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.40) to ($2.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acrivon Therapeutics is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acrivon Therapeutics is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcrivon Therapeutics has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Acrivon Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Acrivon Therapeutics Stock (NASDAQ:ACRV)Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Read More ACRV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRV Stock News HeadlinesSeptember 7 at 6:59 AM | americanbankingnews.comAcrivon Therapeutics (NASDAQ:ACRV) Given "Buy" Rating at Piper Sandler CompaniesSeptember 5 at 1:08 PM | finance.yahoo.comWe're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash WiselySeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 28, 2024 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 28, 2024 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $22.00 Average Target Price from AnalystsAugust 16, 2024 | markets.businessinsider.comAcrivon Therapeutics: A Buy Rating Justified by Clinical Advances and Financial StabilityAugust 16, 2024 | uk.investing.comBMO maintains Outperform rating on Acrivon Therapeutics sharesAugust 13, 2024 | markets.businessinsider.comAcrivon Therapeutics, Inc.: Strong Buy Rating on Robust Financials and Promising Clinical DataSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 13, 2024 | markets.businessinsider.comPromising Acrivon Trial Results and Market Opportunity Support Buy RatingAugust 13, 2024 | finance.yahoo.comAcrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed on Acrivon Therapeutics Amid Anticipated Clinical Updates and Novel Treatment ApproachesMay 29, 2024 | globenewswire.comAcrivon Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)May 14, 2024 | investorplace.comACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comAcrivon Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 11, 2024 | morningstar.comAcrivon Therapeutics Inc ACRVMay 9, 2024 | finance.yahoo.comWhile institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownershipSee More Headlines Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACRV CUSIPN/A CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$23.14 High Stock Price Target$30.00 Low Stock Price Target$14.00 Potential Upside/Downside+186.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.31% Return on Assets-43.10% Debt Debt-to-Equity RatioN/A Current Ratio16.16 Quick Ratio16.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.98 per share Price / Book1.16Miscellaneous Outstanding Shares30,877,000Free Float28,252,000Market Cap$249.49 million OptionableNot Optionable Beta0.81 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Peter Blume-Jensen M.D. (Age 61)Ph.D., Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Comp: $977.7kMs. Kristina Masson M.B.A. (Age 43)Ph.D., Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director Comp: $739.78kMs. Mary-Alice Miller J.D. (Age 50)Chief Legal Officer Comp: $587.11kMr. Rasmus Holm-Jorgensen (Age 52)Chief Financial Officer Comp: $1MDr. Eric J. Devroe Ph.D. (Age 45)Chief Operating Officer Comp: $614.78kMs. Katharine Peterson CPAVice President of Finance & AccountingDr. Adam D. Levy M.B.A.Ph.D., Senior VP and Head of Investor Relations & Corporate AffairsMr. Bruce CloseVice President of Quality & ComplianceMs. Parvin MiahVP & Head of Human ResourcesDr. Erick Gamelin M.D. (Age 66)Ph.D., Chief Development Officer Comp: $480.72kMore ExecutivesKey CompetitorsAutolus TherapeuticsNASDAQ:AUTLTarsus PharmaceuticalsNASDAQ:TARSBicycle TherapeuticsNASDAQ:BCYCAnaptysBioNASDAQ:ANABPraxis Precision MedicinesNASDAQ:PRAXView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCBought 2,353,000 shares on 8/16/2024Ownership: 17.362%Marshall Wace LLPBought 351,397 shares on 8/14/2024Ownership: 3.073%Sands Capital Ventures LLCBought 470,000 shares on 8/13/2024Ownership: 6.874%XTX Topco LtdBought 10,493 shares on 8/12/2024Ownership: 0.034%Dimensional Fund Advisors LPBought 10,066 shares on 8/9/2024Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions ACRV Stock Analysis - Frequently Asked Questions How have ACRV shares performed this year? Acrivon Therapeutics' stock was trading at $4.92 at the beginning of 2024. Since then, ACRV shares have increased by 64.2% and is now trading at $8.08. View the best growth stocks for 2024 here. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.08. When did Acrivon Therapeutics IPO? Acrivon Therapeutics (ACRV) raised $100 million in an initial public offering on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO. Who are Acrivon Therapeutics' major shareholders? Acrivon Therapeutics' top institutional shareholders include Perceptive Advisors LLC (17.36%), Sands Capital Ventures LLC (6.87%), Marshall Wace LLP (3.07%) and Renaissance Technologies LLC (0.18%). Insiders that own company stock include Perceptive Advisors Llc, Ra Capital Management, LP and Ltd Chione. View institutional ownership trends. How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACRV) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.